Phase II Study of Cetuximab (Erbitux®) in Combination With Modified FOLFIRI in Patients With Advanced Gastric Cancer Who Failed to First-line Chemotherapy
Up to now, although FU based, cisplatin based and taxane based regimen, and ECF regimen have
been suggested as the first line therapy for A/MGC by FDA, there is no standard regimen for
patients with A/MGC as second line treatment. Based on the promising results of cetuximab
combined with FOLFIRI in metastatic colorectal cancer, we design this clinical trial to
evaluate the efficacy and safety of cetuximab combined with FOLFIRI for A/MGC patients as a
second line treatment.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
time to progression
every 8 weeks
Jin Li, PhD, M.D.
China: Ethics Committee
EMR 62202- 806